Evommune soars after eczema therapy shows promise in mid-stage trial

Shares of drug developer Evommune EVMN.N jump 50% to $25.3; highest since its IPO in November 2025

Co says its experimental therapy, EVO301, met the main goal of a mid-stage trial, when tested in patients with moderate-to-severe atopic dermatitis

Atopic dermatitis, or eczema, is a chronic skin condition causing dry, itchy, inflamed skin due to a faulty skin barrier and overactive immune response

In a 70-patient trial, 23% of patients on EVO301 had clear or almost clear skin with a meaningful improvement, compared with patients on placebo

EVO301 is an injectable protein drug designed to block IL‑18, an inflammatory signal that is overactive in conditions like atopic dermatitis

Patients on co's therapy showed statistically significant reduction in their EASI scores - a standard measure of eczema severity - compared with people who received placebo by week 4, 8 and 12 of the study

EVMN says it is also evaluating potential additional indications for EVO301, including ulcerative colitis

Up to last close, stock has been down 16% in last 12 months